Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $3.0 million.

  • Veracyte's Cash from Financing Activities fell 7106.62% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year decrease of 18532.66%. This contributed to the annual value of $4.9 million for FY2024, which is 7285.87% up from last year.
  • Latest data reveals that Veracyte reported Cash from Financing Activities of $3.0 million as of Q3 2025, which was down 7106.62% from -$566000.0 recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Cash from Financing Activities peaked at $591.0 million during Q1 2021, and registered a low of -$6.5 million during Q1 2025.
  • Moreover, its 5-year median value for Cash from Financing Activities was $397000.0 (2023), whereas its average is $31.8 million.
  • As far as peak fluctuations go, Veracyte's Cash from Financing Activities soared by 26996849.32% in 2021, and later tumbled by 504545.45% in 2025.
  • Over the past 5 years, Veracyte's Cash from Financing Activities (Quarter) stood at $173000.0 in 2021, then plummeted by 46.24% to $93000.0 in 2022, then skyrocketed by 593.55% to $645000.0 in 2023, then crashed by 799.22% to -$4.5 million in 2024, then skyrocketed by 166.01% to $3.0 million in 2025.
  • Its Cash from Financing Activities stands at $3.0 million for Q3 2025, versus -$566000.0 for Q2 2025 and -$6.5 million for Q1 2025.